Immuno-Oncology Market Size, Share, Growth, And Industry Analysis, By Type (Immune Checkpoint Inhibitors, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy and Others), By Application (Hospitals, Drugstores and Others), Regional Insights, and Forecast from 2023 to 2030

Updated On: 13 November 2023

Immuno-Oncology Market Report Overview

• 

• Request a Free Sample to learn more about this report

Immuno-Oncology Market Size is expected to grow from 43650 million in 2021 to USD 116680 million by 2028 at a Compound Annual Growth (CAGR) of 14.9% from 2021 to 2028.

A cutting-edge field of study called immuno-oncology aims to support the body's immune system in battling cancer. The immune system may be strengthened or suppressed by drugs used to treat cancer to bolster the body's defences against cancer, infections, and other illnesses. It uses compounds produced by the body or in a lab to strengthen the immune system and aid in the body's search for and elimination of cancer cells. These are drugs that block certain molecules on the surface of cancer cells or immune cells, allowing the immune system to recognize and attack the cancer cells more effectively. 

COVID-19 Impact: Pandemic Hamper the Demand of Immuno-Oncology to Market Growth

The COVID-19 pandemic has had a significant impact on Immuno-Oncology (IO), both in terms of research and clinical practice. many IO clinical trials have been disrupted or delayed due to the pandemic, as hospitals and clinics shifted their focus and resources to treating COVID-19 patients. This has led to a slowdown in the development of new IO therapies, as well as delays in the approval of existing therapies. 

Latest Trends

"Increasing Demand for Immune Checkpoint Inhibitors to Support Market Expansion "

These drugs have been very successful in treating certain types of cancer, but they do not work for everyone. Researchers are now exploring ways to combine checkpoint inhibitors with other drugs or therapies to improve their effectiveness. This approach involves modifying a patient's own T cells to recognize and attack cancer cells. Researchers are exploring ways to combine adoptive cell therapy with other IO therapies to enhance their effectiveness.

Immuno-Oncology Market Segmentation

• 

• Request a Free Sample to learn more about this report

• By Type Analysis

According to type, the immuno-oncology market can be segmented into immune checkpoint inhibitors, cytokine-based immunotherapy, cancer vaccines, CAR-T cell therapy and others.

In terms of type, the immune checkpoint inhibitors are anticipated to be the largest segment during the forecast period.  

• By Application Analysis

Based on application, the immuno-oncology market can be divided into hospitals, drugstores, and others.

In terms of application, the hospitals market is projected to hold the largest immuno-oncology market share through 2028. 

Driving Factors

"Success in clinical trials will Boost Market Growth "

IO is the success of IO therapies in clinical trials. IO therapies have shown remarkable results in treating certain types of cancer, including melanoma, lung cancer, and bladder cancer, among others. This success has generated interest and investment in the field, leading to further research and development. 

"Better Understanding of the Immune System will Fuel Market Growth "

Advances in our understanding of the immune system have also contributed to the growth of IO. Researchers now have a better understanding of how the immune system recognizes and attacks cancer cells, and how tumors can evade the immune system. This knowledge has led to the development of new IO therapies that target different aspects of the immune system. IO therapies can be tailored to individual patients based on their specific cancer type and immune profile. This personalized approach has the potential to improve outcomes and reduce side effects.

Restraining Factors

"Limited Patient Response and Side Effects Will Limit Market Growth"

While IO therapies have shown remarkable success in treating certain types of cancer, they do not work for all patients. This limited response rate can be a restraining factor, as it may limit the widespread adoption of IO therapies. IO therapies can cause significant side effects, including autoimmune reactions and inflammation. These side effects can be severe and may limit the use of IO therapies in certain patients. 

Immuno-Oncology Market Regional Insights

• 

• Request a Free Sample to learn more about this report

"The North America Region will Dominate Market Due to Strong Demand of Clinical Trials"

North America is a major player in the IO space, with a large number of clinical trials taking place in the region. home to many of the world's leading IO companies, and the FDA has been relatively quick to approve new IO therapies. Several clinical trials are currently taking place in the region, and there is growing interest from IO companies.

Europe is also a major player in IO, with several companies and academic institutions conducting IO research and development. The European Medicines Agency (EMA) has also approved several IO therapies, although the approval process can be slower.

Key Industry Players

"Adoption Aluminum Recycling Services by Key Players Influencing Market Development"

The top key players in the market are Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals. Most of the top players hold the immuno-oncology market share. In addition, the strategies to develop new technologies, capital investment in R&D, improve product quality, acquisitions, mergers, and compete for the immuno-oncology market growth in the competition help them to perpetuate their position and value in the market. Besides, collaboration with other companies & extensive possession of market shares by the key players stimulates the immuno-oncology market.  

List of Market Players Profiled

• Bristol-Myers Squibb (U.S.)
• Merck & Co., Inc. (U.S.)
• Roche AG (Switzerland)
• AstraZeneca, Plc (UK.)
• Sanofi S.A. (France)
• Dendreon Pharmaceuticals (U.S.)
• Novartis (Switzerland)
• Gilead Sciences Inc. (U.S.)
• Merck KGaA (Germany)

Report Coverage

This report examines an understanding of the immuno-oncology market’s size, share, growth rate, segmentation by type, application, key players, and previous and current market scenarios. The report also collects the market’s precise data and forecasts by market experts. Also, it describes the study of this industry’s financial performance, investments, growth, innovation marks, and new product launches by the top companies and offers deep insights into the current market structure, competitive analysis based on key players, key driving forces, and restraints that affect the demand for growth, opportunities, and risks.

Furthermore, the post-COVID-19 pandemic’s effects on international market restrictions and a deep understanding of how the industry will recover, and strategies are also stated in the report. The competitive landscape has also been examined in detail to provide clarification of the competitive landscape.

This report also discloses the research based on methodologies that define price trend analysis of target companies, collection of data, statistics, target competitors, import-export, information, and previous years’ records based on market sales. Moreover, all the significant factors which influence the market such as small or medium business industry, macro-economic indicators, value chain analysis, and demand-side dynamics, with all the major business players have been explained in detail. This analysis is subject to modification if the key players and feasible analysis of market dynamics change.